Company Overview and News
InFocus, which has a licensing deal with Foxconn, will use the $10 million investment to expand its operations in the world’s second largest telecom market
InFocus, which has a licensing deal with contract handset maker Foxconn, will invest $10 million in the Indian market to expand its operations in the world's second largest mobile phone market. In its second attempt to tap into the market here, InFocus will line up about 16 feature phones and smartphones this year as it eyes a spot among the top 5 handset players in the country.
InFocus, which has a licensing deal with contract handset maker Foxconn, will invest USD 10 million in the Indian market to expand its operations in the world's second largest telecom market.
-- HMD Global entra hoy en el mercado para crear una nueva generación de teléfonos móviles marca Nokia a través de un acuerdo exclusivo de licencia de marca por 10 años -- Con efecto inmediato, HMD tendrá la propiedad del negocio actual de teléfonos de funciones básicas marca Nokia, proporcionando escala y alcance de mercado mundial -- Anuncian el equipo de dirección de HMD Global; ambición de convertirse en un factor importante en el mercado mundial de los teléfonos inteligentes -- El modelo de asociación estratégica con participantes líderes de la industria y el conocimiento de categoría mundial llevarán la mejor experiencia en teléfonos móviles de Nokia a los consumidores internacionales -- Los nuevos smartphones de Nokia con el sistema operativo Android estarán a la venta en la primera mitad de 2017
-- HMD Global entra hoje no mercado, para criar uma nova geração de telefones celulares da marca Nokia através de um acordo exclusivo de licenciamento da marca por um período de 10 anos -- Com efeito imediato, a HMD passa a ser proprietária do negócio existente de telefones com recursos da marca Nokia, fornecendo alcance e escala no mercado global -- A equipe de liderança da HMD foi anunciada; ambição de se tornar uma participante significativa no mercado global de smartphones -- Modelo de parceria estratégica com participantes líderes da indústria e especialização de classe mundial para levar a melhor de todas as experiências com telefone celular Nokia para consumidores de todo o mundo -- Novos smartphones Nokia com sistema operacional Android estarão disponíveis no primeiro semestre de 2017
Foxconn International Holdings (OTCPK:FXCNF), the world’s largest contract manufacturer of electronic components, made notorious last year by a rash of employee suicides at its Chinese factories, recently published its half-yearly financial results, which showed that its annual labor costs per employee have risen by a third over the past year, to $2,900.
After around 2,000 workers brawled at a Foxconn Technology Group (OTCPK:FXCNF) dormitory, the Taiwanese electronics maker said it would close a plant in China on Monday, according to Reuters. Although the Apple Inc. (NASDAQ:AAPL) product supplier continues coming under fire, the international disclosure about its corporate governance remains relatively murky, signaling that its global clients don't require much information in order to strike a deal.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...